Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
about
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryBone marrow endothelium-targeted therapeutics for metastatic breast cancerZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massPrevention of bone metastases and management of bone health in early breast cancer.Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian GuidelineCost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.Current and emerging treatment strategies for breast cancer-induced bone loss.Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancerAntiresorptive therapy in the management of cancer treatment-induced bone loss.Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).
P2860
Q28295416-9F2FA745-7121-44C5-92CD-CFE1C868139AQ33943576-B118A7EE-21BE-4A30-951D-AA7BD30AA421Q34389524-6FDAA0A0-3429-4981-88A5-0051FE3608FFQ34613485-04DFF6F3-B88B-486B-881B-A85A5CAC05F1Q35593300-F5D2C038-7D58-467D-AB90-3C97CA5F86F6Q35750472-853EA25E-503D-428B-B3F4-990180B172EEQ35934290-13E66007-04E9-4164-96C9-2BC3ED98E135Q36187103-1DA22DBB-004C-48D5-9428-D41326393A4BQ36337775-04BF1ACB-DA3E-47E5-AAE5-8045A423848EQ37355790-AE0CD619-2433-46CA-832C-B3E00F542661Q37356084-4493C203-53D1-41D4-8B7F-711401B6F0C4Q38313112-C6371D60-2C78-4EA4-AC2F-74B02BA84878Q42363605-56A1022B-674F-4C69-9450-D02B7018E893Q42570772-DB054C07-F37B-4323-BA33-7D21CD2FC832Q51393764-D1CAFAD4-220E-48DA-B432-142E66EB318F
P2860
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Zoledronic acid for treatment ...... t aromatase inhibitor therapy.
@ast
Zoledronic acid for treatment ...... t aromatase inhibitor therapy.
@en
type
label
Zoledronic acid for treatment ...... t aromatase inhibitor therapy.
@ast
Zoledronic acid for treatment ...... t aromatase inhibitor therapy.
@en
prefLabel
Zoledronic acid for treatment ...... t aromatase inhibitor therapy.
@ast
Zoledronic acid for treatment ...... t aromatase inhibitor therapy.
@en
P2093
P2860
P1433
P1476
Zoledronic acid for treatment ...... t aromatase inhibitor therapy.
@en
P2093
Bassam I Mattar
Charles L Loprinzi
David B Johnson
Edith A Perez
Jeff A Sloan
Pamela J Atherton
Pavan S Reddy
Robert J Dalton
Shaker R Dakhil
Stephanie L Hines
P2860
P356
10.1016/J.BREAST.2009.12.001
P577
2010-01-15T00:00:00Z